title: Parallel paths to predictive biomarkers in oncology: Uncoupling of emergent biomarker development and phase III trial execution.
abstract: It is within pivotal phase III clinical trials that predictive biomarkers have the greatest potential to affect clinical practice by targeting drugs under development to relevant patient subgroups. Predictive biomarkers can be integrated into phase III clinical trials by a variety of approaches, including trial designs that uncouple the processes and actively anticipate the emergence of new biomarkers during trial execution. Here we describe the various approaches in an oncology context.
authors.affiliation: Amgen, Thousand Oaks, CA 91320, USA. public@robertsikorski.com
authors.forename: Robert
authors.initials: R
authors.lastname: Sikorski
authors.forename: Bin
authors.initials: B
authors.lastname: Yao
mesh_terms: D014408:Biomarkers, Tumor; D017326:Clinical Trials, Phase III as Topic; D011905:Genes, ras; D006801:Humans; D008495:Medical Oncology
chemical_list: D014408:Biomarkers, Tumor